Cargando…
Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
Barrett’s esophagus progresses to high-grade dysplasia or cancer along the well-established metaplasia-dysplasia-adenocarcinoma sequence. The aim of this study was to evaluate the value of p53, Ki67, and toll-like receptor 5 (TLR5) in prediction of malignant progression of Barrett’s metaplasia and l...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485097/ https://www.ncbi.nlm.nih.gov/pubmed/35614270 http://dx.doi.org/10.1007/s00428-022-03340-5 |
_version_ | 1784792016587063296 |
---|---|
author | Helminen, Olli Melkko, Jukka Saarnio, Juha Sihvo, Eero Kuopio, Teijo Ohtonen, Pasi Kauppila, Joonas H. Karttunen, Tuomo J. Huhta, Heikki |
author_facet | Helminen, Olli Melkko, Jukka Saarnio, Juha Sihvo, Eero Kuopio, Teijo Ohtonen, Pasi Kauppila, Joonas H. Karttunen, Tuomo J. Huhta, Heikki |
author_sort | Helminen, Olli |
collection | PubMed |
description | Barrett’s esophagus progresses to high-grade dysplasia or cancer along the well-established metaplasia-dysplasia-adenocarcinoma sequence. The aim of this study was to evaluate the value of p53, Ki67, and toll-like receptor 5 (TLR5) in prediction of malignant progression of Barrett’s metaplasia and low-grade dysplasia. This was a retrospective matched case–control study based on Northern and Central Finland population. Patients diagnosed with esophageal high-grade dysplasia or adenocarcinoma were included. From these patients, all previous endoscopy samples were obtained along with original diagnostic HE-slides and clinical data. Age- and sex-matched patients with non-progressing Barrett’s metaplasia and low-grade dysplasia confirmed with follow-up endoscopies were used as controls. Two gastrointestinal pathologist re-reviewed all original HE-slides, and newly made sections to confirm representative tissue material blinded from clinical data. p53, Ki67, and TLR5 were immunohistochemically stained. Final cohort included 45 patients with progressive Barrett’s metaplasia (n = 21) or low-grade dysplasia (n = 24), and 92 patients with non-progressive Barrett’s metaplasia (n = 52) or low-grade dysplasia (n = 40). In Barrett’s metaplasia, aberrant p53 expression was observed in 6% of samples in progressors and 0% in non-progressors. In low-grade dysplasia, aberrant p53 was seen in 56% of samples in progressors and 17% in non-progressors (Odd’s ratio 6.7, 95% CI 1.8–24.6). Ki67 or TLR5 showed no association with disease progression. In this matched case–control study, p53 expression associated with a high risk of malignant progression in Barrett’s low-grade dysplasia. Routine staining of p53 is indicated in expert confirmed low-grade dysplasia. |
format | Online Article Text |
id | pubmed-9485097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94850972022-09-21 Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study Helminen, Olli Melkko, Jukka Saarnio, Juha Sihvo, Eero Kuopio, Teijo Ohtonen, Pasi Kauppila, Joonas H. Karttunen, Tuomo J. Huhta, Heikki Virchows Arch Original Article Barrett’s esophagus progresses to high-grade dysplasia or cancer along the well-established metaplasia-dysplasia-adenocarcinoma sequence. The aim of this study was to evaluate the value of p53, Ki67, and toll-like receptor 5 (TLR5) in prediction of malignant progression of Barrett’s metaplasia and low-grade dysplasia. This was a retrospective matched case–control study based on Northern and Central Finland population. Patients diagnosed with esophageal high-grade dysplasia or adenocarcinoma were included. From these patients, all previous endoscopy samples were obtained along with original diagnostic HE-slides and clinical data. Age- and sex-matched patients with non-progressing Barrett’s metaplasia and low-grade dysplasia confirmed with follow-up endoscopies were used as controls. Two gastrointestinal pathologist re-reviewed all original HE-slides, and newly made sections to confirm representative tissue material blinded from clinical data. p53, Ki67, and TLR5 were immunohistochemically stained. Final cohort included 45 patients with progressive Barrett’s metaplasia (n = 21) or low-grade dysplasia (n = 24), and 92 patients with non-progressive Barrett’s metaplasia (n = 52) or low-grade dysplasia (n = 40). In Barrett’s metaplasia, aberrant p53 expression was observed in 6% of samples in progressors and 0% in non-progressors. In low-grade dysplasia, aberrant p53 was seen in 56% of samples in progressors and 17% in non-progressors (Odd’s ratio 6.7, 95% CI 1.8–24.6). Ki67 or TLR5 showed no association with disease progression. In this matched case–control study, p53 expression associated with a high risk of malignant progression in Barrett’s low-grade dysplasia. Routine staining of p53 is indicated in expert confirmed low-grade dysplasia. Springer Berlin Heidelberg 2022-05-26 2022 /pmc/articles/PMC9485097/ /pubmed/35614270 http://dx.doi.org/10.1007/s00428-022-03340-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Helminen, Olli Melkko, Jukka Saarnio, Juha Sihvo, Eero Kuopio, Teijo Ohtonen, Pasi Kauppila, Joonas H. Karttunen, Tuomo J. Huhta, Heikki Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study |
title | Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study |
title_full | Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study |
title_fullStr | Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study |
title_full_unstemmed | Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study |
title_short | Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study |
title_sort | predictive value of p53, ki67 and tlr5 in neoplastic progression of barrett’s esophagus: a matched case–control study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485097/ https://www.ncbi.nlm.nih.gov/pubmed/35614270 http://dx.doi.org/10.1007/s00428-022-03340-5 |
work_keys_str_mv | AT helminenolli predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT melkkojukka predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT saarniojuha predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT sihvoeero predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT kuopioteijo predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT ohtonenpasi predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT kauppilajoonash predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT karttunentuomoj predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy AT huhtaheikki predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy |